Stockreport

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. - Ordinary Shares  (PBM) 
PDF   Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder [Read more]